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ABSTRACT
BACKGROUND AND PURPOSE: Thrombus CT characteristics might be useful for patient selection for intra-arterial treatment. Our
objective was to study the association of thrombus CT characteristics with outcome and treatment effect in patients with acute ischemic
stroke.
MATERIALS AND METHODS: We included 199 patients for whom thin-section NCCT and CTA within 30 minutes from each other were
available in theMulticenter RandomizedClinical Trial of Endovascular Treatment for Acute ischemic stroke in theNetherlands (MRCLEAN)
study. We assessed the following thrombus characteristics: location, distance from ICA terminus to thrombus, length, volume, absolute
and relative density on NCCT, and perviousness. Associations of thrombus characteristics with outcome were estimated with univariable
and multivariable ordinal logistic regression as an OR for a shift toward better outcome on the mRS. Interaction terms were used to
investigate treatment-effect modiﬁcation by thrombus characteristics.
RESULTS: In univariate analysis, only the distance from the ICA terminus to the thrombus, length of 8 mm, and perviousness were
associated with functional outcome. Relative thrombus density on CTA was independently associated with functional outcome with an
adjusted common OR of 1.21 per 10% (95% CI, 1.02–1.43; P .029). There was no treatment-effect modiﬁcation by any of the thrombus CT
characteristics.
CONCLUSIONS: In our study on patients with large-vessel occlusion of the anterior circulation, CT thrombus characteristics appear
useful for predicting functional outcome. However, in our study cohort, the effect of intra-arterial treatment was independent of the
thrombus CT characteristics. Therefore, no arguments were provided to select patients for intra-arterial treatment using thrombus CT
characteristics.
ABBREVIATIONS: DT  distance from the ICA terminus to the thrombus; IAT  intra-arterial treatment; ICA-T  ICA terminus; IQR  interquartile range; MR
CLEANMulticenter Randomized Clinical Trial of Endovascular Treatment for Acute ischemic stroke in the Netherlands
Intra-arterial treatment (IAT) of acute ischemic stroke with re-trievable stents for patients with a confirmed intracranial arte-
rial occlusion of the anterior circulation has proved beneficial and
safe in multiple randomized controlled trials.1-5 Several studies
have found a relation between radiologic imaging characteristics
of the thrombus and functional outcome, whichmight have value
in the prediction of the efficacy of IAT. For example, multiple
studies have suggested that patients with a clot longer than 8 mm
on NCCT do not respond well to IV alteplase but might profit
from IAT.6,7 Furthermore, a previous study observed that com-
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pared with IV alteplase alone, IAT after IV alteplase leads to better
outcomes in patients with a distance from the ICA terminus
(ICA-T) to the thrombus (DT) shorter than 16 mm.8 Also, it was
found that a thrombuswith higher absolute or relativeHounsfield
units onNCCT is predictive of successful recanalization withme-
chanical thrombectomy or intravenous alteplase.9-12Moreover, it
was recently shown that thrombus perviousness, which is a mea-
sure of the amount of contrast penetration in the thrombus on
CTA, is strongly associated with functional outcome.13 On the
basis of these observations, we hypothesized that thrombus CT
characteristics have the potential to be used for selection of
patients who are likely to benefit from IAT. We aimed to de-
termine which thrombus CT characteristics are associated with
functional outcome in patients with acute ischemic stroke due
to a proximal intracranial occlusion enrolled in the Multi-
center Randomized Clinical Trial of Endovascular Treatment
for Acute ischemic stroke in the Netherlands (MR CLEAN)
study. Moreover, we aimed to determine whether the efficacy
of IAT on functional outcome was modified by the thrombus
CT characteristics.
MATERIALS AND METHODS
Patient Selection
All patients enrolled inMRCLEANwith thin-section (2.5mm)
baseline NCCT and CTA acquired within 30 minutes from each
other on the same scanner were included in this study (n 233).
CT datawith toomuch noise (n 8), severemotion artifacts (n
22), insufficient contrast on CTA (n  1), and incomplete ROI
(n 3) were excluded; thus, data from 199 patients were available
for further analysis. In MR CLEAN, the effect of IAT versus best
medical treatment, including IV alteplase, was investigated in pa-
tients with acute ischemic stroke. Patients enrolled inMRCLEAN
had a proximal intracranial arterial occlusion of the anterior cir-
culation confirmed on vessel imaging. Permission of the ethics
committee and institutional review board was given, and patients
or their legal representatives signed informed consents. The pro-
tocol and a detailed description of the methods of MR CLEAN
have been published previously.14
Image Analysis
We determined the following thrombus characteristics on base-
line NCCT and CTA imaging: location, DT, length, volume,
absolute and relative attenuation on NCCT, and thrombus pervi-
ousness measures: absolute and relative density on CTA, attenu-
ation increase, and void fraction.13 Location of the thrombus
(M1, M2, A1, A2, ICA, or ICA-T) was determined on CTA by
expert neuroradiologists.1 The length of the thrombus was mea-
sured on NCCT with the aid of coregistered CTA, with an in-
house-developed MeVisLab interface (www.mevislab.de).15 A
trained user (J.B., with 3 years of experience in neuroimaging
research), blinded to clinical information, placed several seed
points in the thrombus (Fig 1). Subsequently, the software deter-
mined the centerline through the thrombus. If needed, the user
could adapt the centerline on multiplanar reformations. The
length of the thrombus was represented by the length of this cen-
terline. With the same program, the DT was measured by placing
several seed points starting in the ICA-T to the proximal border of
the thrombus (Fig 2). The volume of the thrombus was calculated
with a semiautomated segmentation method adapted from San-
tos et al.15 The centerline already determined for the length mea-
surement was subsequently used in the volume calculation.
Density measurement of the thrombus and contralateral ves-
sel segment was performed on NCCT and coregistered CTA by a
trained observer (M.d.B., with 1 year of experience), blinded to
clinical information, with the in-house-developed MeVisLab in-
terface.13 Themean thrombus densitywas calculated by averaging
the Hounsfield units of 3 manually placed ROIs of the thrombus.
Relative density was calculated by dividing the mean Hounsfield
unit of the thrombus by the mean Hounsfield unit of the con-
tralateral vessel segment.11
We included thrombus perviousness measures estimating the
permeability by quantifying the contrast agent penetration in the
thrombus on CTA. Absolute and relative thrombus densities on
CTA were derived in a manner similar to that of the density mea-
surement on NCCT. Attenuation increase was determined by
subtracting themean density of the thrombus onNCCT from the
FIG 1. Lengthmeasurement. Placement of seed points in the thrombus by the observer. Subsequently, the software determined the centerline
through the thrombus, which represents the length of the thrombus. Top row from left to right: sagittal view NCCT, coronal view NCCT, axial
view NCCT. Bottom row from left to right: sagittal view CTA, coronal view CTA, axial view CTA.
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mean density on CTA. Void fraction was the ratio between the
attenuation increase of the thrombus and the attenuation increase
of the contralateral vessel segment.13
Statistical Analysis
Association with Outcome. The primary outcome measure was
the full modified Rankin Scale score at 90 days. The mRS is an
ordered categoric scale to measure functional disability, ranging
from 0 (no symptoms) to 6 (death). A score of2 indicates func-
tional independence.16 The association of thrombus characteris-
tics with functional outcome was estimated with univariable and
multivariable ordinal logistic regression and was presented as a
commonOR for a shift in the direction of a better outcome on the
mRS.16,17 The common odds ratio measured the likelihood that
the presence of a certain thrombus characteristic would lead to
lower modified Rankin Scale scores, compared with the absence
of this thrombus characteristic (shift analysis).17
If one analyzes themRS on an ordinal scale, the ordinal nature
of the mRS is preserved; therefore, the statistical power is in-
creased compared with dichotomized analyses.18
We adjusted for differences in patient characteristics by in-
cluding the following baseline characteristics as covariates in the
multivariable analysis: age, sex, atrial fibrillation, diabetes melli-
tus, time from onset to randomization, previous stroke, and
stroke severity assessed by the NIHSS. We included all thrombus
characteristics with a P value .10 (in the univariable analysis) in
the multivariable analysis.
To avoid multicollinearity, we implemented thrombus char-
acteristics that were more than moderately correlated with each
other (Spearman correlation or point-biserial correlation of
0.5) in separate models. Of the correlated characteristics, we
first included the characteristics with the lowest univariable P
value in the multivariable model. Subsequently, we alternately
replaced a correlated characteristic for the others in themultivari-
able model.
Location of the thrombus (ICA-T, n 46; M1, n 131; M2,
n  22) was dichotomized as an ICA-T occlusion versus a non-
ICA-T occlusion. Because it has been suggested that patients with
a thrombus of8mmor aDT of16mmdo not respondwell to
intravenous alteplase,6-8 we have also introduced the dichoto-
mized thrombus length of8 mm and the DT of16 mm in the
analysis.
Secondary outcome measures were the following: the absence
of an intracranial occlusion on follow-up CTA and final infarct
volume on follow-up NCCT.19 For the patients who underwent
successful IAT reperfusion, modified Thrombolysis in Cerebral
Infarction 2B or 320 was also used as a secondary outcome mea-
sure. For dichotomized outcome measures, univariable logistic
regression analysis was performed, and the association was pre-
sented as an OR. For final infarct volume, univariable linear re-
gression was performed, and the association was reported as B
coefficients. The multivariable analysis to determine the associa-
tion of the thrombus characteristics with final infarct volume or
absence of occlusion on follow-upCTAwas performed, similar to
the multivariable analysis for the mRS.
Treatment-Effect Modiﬁcation. We investigated whether throm-
bus characteristics had a treatment-effectmodification by analyzing
whether there was interaction with treatment allocation in the
prediction of functional outcome, using a multivariable ordinal
logistic regression model, including the thrombus characteristic
of interest, treatment allocation, and the multiplicative inter-
action term of these variables. We also included the baseline
characteristics and thrombus characteristics with a univariable
P value  .1 in a multivariable ordinal logistic regression
model. Of the correlated characteristics, we included only the
thrombus characteristics with the lowest univariable P value in
the multivariable model.
The effect of outliers was minimized by truncation of contin-
uous CT thrombus characteristics (length, volume, DT, absolute
and relative density on NCCT, and perviousness) at the 2.5th and
97.5th percentiles.21 STATA/SE 131 (StataCorp, College Station
Texas) was used for all statistical analyses.
RESULTS
The mean age was 65 years (range, 31–93 years), and 62% (124/
199) were men. Table 1 shows the baseline characteristics of the
study cohort, and Table 2 shows the baseline characteristics strat-
ified by treatment. Except for the percentage of patients allocated
to IAT, the baseline characteristics of the full MR CLEAN cohort
and this study cohort were similar. In our study cohort, 39%
FIG 2. Distance from the ICA-T to the thrombus. Placement of seed points in the vessel from the ICA-T to the thrombus by the observer.
Subsequently, the software determined the centerline through the vessel, which represents the distance from the ICA-T to the thrombus. Left:
coronal view CTA. Right: axial view CTA.
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(78/199) of the patients underwent IAT comparedwith 47%(233/
500) in the MR CLEAN cohort. The successful reperfusion rate
was 59% (115/194). The median thrombus length was 15.6 mm
(interquartile range [IQR], 10.3–22.2 mm), the median DT was
6.4 mm (IQR, 0.0–13.5 mm), and the median density on NCCT
was 49.0HU (IQR, 44.5–55.4HU). If the thrombuswas located in
the ICA-T, the DT was 0 mm. In 13 patients, we were unable to
determine the length of the thrombus due to lack of contrast in the
extracranial ICA.
In this study cohort, 15% (30/199) of the thrombi were 8
mm and 18% (35/199) had a DT 16 mm. The median relative
CTA thrombus density was 29.8% (IQR, 21.4%–40.8%), the me-
dian thrombus attenuation increase was 11.4 HU (IQR, 0.1–22.5
HU), and the median thrombus void fraction was 6.0% (IQR,
0.08%–15.4%).
Associations with Outcome
DT, length of 8 mm, and the perviousness measures (ie, abso-
lute and relative CTA density, attenuation increase, and void frac-
tion) were associated with functional outcome in the univariable
analysis (P  .05) (On-line Table 1). Length and length of 8
mm, volume and length, DT and DT  16 mm, DT and the
presence of an ICA-T, and the perviousness measures were corre-
lated with each other (see On-line Table 2 for the correlation
coefficients). Only relative thrombus density on CTA was an in-
dependent predictor of functional outcome in the multivariable
analysis, with an adjusted common OR of 1.21 per 10% (95% CI,
1.02–1.43) (P .029) (see On-line Table 1 for adjusted common
ORs). Thrombus volume, DT, DT  16 mm, NCCT thrombus
density, and CTA attenuation increase were associated with the
absence of an intracranial occlusion on follow-up CTA (On-line
Table 1). In the multivariable analysis, none of the thrombus CT
characteristics were associated with the absence of intracranial
occlusion on follow-up CTA (P .05) (On-line Table 1). Length
of8 mm, thrombus volume, DT, DT 16 mm, the presence of
ICA-T, NCCT thrombus density, CTA attenuation increase, and
void fraction were associated with final infarct volume (On-line
Table 1). In the multivariable analysis, none of the thrombus CT
characteristics were associated with final infarct volume (On-line
Table 1).
Table 1: Baseline characteristics of the full MR CLEAN cohort and subgroups included and not included in this study
MR CLEAN Subgroup
Included (n = 199)
MR CLEAN Not
Included (n = 301)
MR CLEAN Full
Cohort (n = 500)
Mean age (yr) 65 (range, 31–93) 66 (range, 23–96) 65 (range, 23–96)
Male sex (%) 62 (124/199) 56 (168/301) 58 (292/500)
Median NIHSS score 18 (IQR, 14–22) 17 (IQR, 15–21) 18 (IQR, 14–22)
Median ASPECTS 9 (IQR, 8–10) 9 (IQR, 7–10) 9 (IQR, 8–10)
Diabetes mellitus (%) 11 (21/199) 16 (47/301) 14 (68/500)
Atrial ﬁbrillation (%) 27 (54/199) 27 (81/301) 27 (135/500)
Previous stroke (%) 10 (20/199) 11 (34/301) 11 (54/500)
IAT (%) 39 (78/199) 51 (155/301) 47 (233/500)
Median thrombus length (mm) (n 186) 15.6 (IQR, 10.3–22.2) (range, 4.8–39.5)
Median thrombus volume (mm3) (n 186) 70.1 (IQR, 49.3–113.3) (range, 6.1–456.7)
Median distance to thrombus (mm) 6.4 (IQR, 0.0–13.5) (range, 0.0–38.2)
T-occlusion (%) 23 (46/199) 29 (88/301) 27 (134/500)
Median density thrombus NCCT (HU) 49.0 (IQR, 44.5–55.4) (range, 33.1–67.8)
Median relative density thrombus NCCT (%) 134.4 (IQR, 116.8–151.7) (range, 65.8–274.4)
Median density thrombus CTA (HU) 61.4 (IQR, 52.6–72.1) (range, 38.5–134.3)
Median relative density thrombus CTA (%) 29.8 (IQR, 21.4–40.8) (range, 12.2–94.7)
Median thrombus attenuation increase (HU) 11.4 (IQR, 0.1–22.5) (range,9.9–80.0)
Median thrombus void fraction (%) 6.0 (IQR, 0.08–15.4) (range,8.9–61.8)
Table 2: Baseline characteristics of the full MR CLEAN subgroups included in this study stratiﬁed by treatment
IAT (n = 78) Control (n = 121)
Mean age (yr) 63 (range, 43–87) 66 (range, 31–93)
Male sex (%) 67 (52/78) 56 (72/121)
Median NIHSS 17 (IQR, 13–21) 19 (IQR, 14–23)
Median ASPECTS 9 (IQR, 8–10) 9 (IQR, 8–10)
Diabetes mellitus (%) 9 (7/78) 12 (14/121)
Atrial ﬁbrillation (%) 22 (17/78) 31 (37/121)
Previous stroke (%) 14 (11/78) 7 (9/121)
Median thrombus length (mm) (n 186) 16.2 (IQR, 11.6–22.0) (range, 4.8–39.5) 15.2 (IQR, 10.3–22.3) (range, 4.8–39.5)
Median thrombus volume (mm3) (n 186) 69.3 (IQR, 51.7–111.9) (range, 6.1–329.0) 70.9 (IQR, 43.8–115.5) (range, 11.4–456.7)
Median distance to thrombus (mm) 6.8 (IQR, 0.0–12.8) (range, 0.0–38.2) 6.4 (IQR, 0.0–13.5) (range, 0.0–38.2)
T-occlusion (%) 26 (20/78) 21 (26/121)
Median density thrombus NCCT (HU) 49.0 (IQR, 45.2–55.2) (range, 33.1–67.8) 48.9 (IQR,44.1–55.4) (range, 33.1–67.8)
Median relative density thrombus NCCT (%) 137.4 (IQR, 116.0–151.4) (range, 84.8–213.0) 131.2 (IQR, 117.7–151.7) (range, 65.8–274.4)
Median density thrombus CTA (HU) 61.2 (IQR, 53.3–68.7) (range, 38.5–134.3) 61.9 (IQR, 52.5–75.1) (range, 38.5–134.3)
Median relative density thrombus CTA (%) 29.6 (IQR, 23.2–37.9) (range, 12.2–94.7) 29.8 (IQR, 20.5–43.9) (range, 12.5–88.7)
Median thrombus attenuation increase (HU) 12.3 (IQR, 0.74–19.6) (range,9.9–80.0) 11.2 (IQR,0.9–28.5) (range,9.9–80.0)
Median thrombus void fraction (%) 5.8 (IQR, 0.99–12.3) (range,8.9–61.8) 6.1 (IQR,0.47–16.8) (range,8.9–61.8)
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Treatment-Effect Modiﬁcation
We observed no significant treatment-effect modification of IAT
with any of the thrombus CT characteristics.
DISCUSSION
In this study cohort of patients with a large-vessel occlusion of the
anterior circulation, DT, length of8 mm, and the perviousness
measures were associated with functional outcome. In our study,
only relative density on CTA was associated with functional out-
come after adjustment for the baseline patient characteristics and
the other thrombus characteristics. We observed that patients
with a higher relative thrombus density on CTA had better func-
tional outcome compared with patients with a lower relative
thrombus density on CTA. We observed no treatment-effect
modification by any of the thrombus CT characteristics. There-
fore, this study provides no arguments to select patients for IAT
using thrombus CT characteristics.
Our study confirms that DT is associated with functional out-
come in univariable analysis.8 In this study cohort, the dichoto-
mized thrombus length of8mmwas associated with functional
outcome, which is in line with a previous study demonstrating
that patients with a thrombus of 8 mm have a better outcome
after IV alteplase.7We observed that increasing thrombus density
on NCCT was associated with persistent occlusion. In contrast,
previous studies have shown that lower absolute and relative
thrombus densities are associated with persistent occlusion in pa-
tientswith anterior circulation occlusion (primarily distalM1 and
M2) treated with IV alteplase.11,12
We observed that the outcome of patients who underwent IAT
was not affected by the density of the thrombus, which is in line
with the findings of previous studies in which there was no differ-
ence in the NCCT density of the thrombus between patients with
and without recanalization after thrombectomy.22,23 However,
several studies using mechanical thrombectomy in a population
of patients with large-vessel occlusion observed that recanaliza-
tion rates were higher for patients with denser thrombi.10,9
Wemeasured CT thrombus characteristics on NCCTwith the
aid of CTA because it was suggested that it is more accurate for
low-density thrombi and for patients with high hematocrit levels,
which might cause overestimation of the length of the throm-
bus.24 DTwas determined onmultiplanar reformations; this pro-
cess gives the user a better impression of the 3D anatomy of the
vasculature compared with previous measurements on transver-
sal maximum intensity projections.25
There are several limitations. We excluded many patients due
to the unavailability of thin-section NCCT (n  252), which is
needed for accurate measurement of the thrombus characteris-
tics.26 In 19%of the patients, IV alteplasewas administered before
CTA; this order could have affected the perviousness measures.
However, there was no difference (P .26) in average pervious-
ness between patients in whom IV alteplase was administered
before or after the CTA. Due to pragmatic reasons, thrombus
density was measured by a trained observer and not by a radiolo-
gist. However, a previous study showed that the density measure-
ments by the trained observers were reproducible and showed
very good agreement with those of the experienced radiologists.27
In this study, multiple tests were performed without adjusting the
P values. This choice could have resulted in a false significant
association between thrombus characteristics and outcome mea-
sures or a false significant treatment-effect modification by the
thrombus characteristics. However, this study found only a sig-
nificant independent association between relative thrombus den-
sity on CTA and themRS, which was also significant (P .001) in
the univariable analysis. This makes it less likely that we have
falsely rejected a true null hypothesis. Furthermore, all the inter-
action terms had a P value  .05 in the adjusted analysis; there-
fore, on the basis of a P value of .05, none of the null hypotheses
were rejected. Adjusting the P values would not change our
conclusions.
The confidence intervals of the interaction terms between the
thrombus characteristics and treatment effect are wide, thus lim-
iting the generalizability of our observation regarding the absence
of significant effect modification.
In this study, relative thrombus density on CTA was indepen-
dently associated with functional outcome. A higher relative
thrombus density on CTAmeans that the contrast penetration in
the thrombus is higher; this feature might be a sign of flow
through a thrombus and is related to early reperfusion.28,29
CONCLUSIONS
In this study cohort, a higher relative density of the thrombus on
CTA was independently associated with better functional out-
come in patients with acute ischemic stroke caused by a large-
vessel occlusion in the anterior circulation. Therefore, CT throm-
bus characteristics appear useful for predicting functional
outcome. However, in patients with a large vessel occlusion of the
anterior circulation, the treatment effect of IAT was independent
of the thrombus CT characteristics. Therefore, no arguments
were provided to select patients for IAT using thrombus CT
characteristics.
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